eversyn | Precise control with glycoengineering

What is an activated sugar?

Activated sugars are high-energy compounds crucial for various applications, including the synthesis of human milk oligosaccharides, specialty carbohydrates, and glycans on therapeutic proteins. Despite their importance, these compounds have been scarce and prohibitively expensive. This scarcity and high cost has presented significant challenges for advancing studies and production processes that rely on these vital compounds.

What do we offer?

Our technology allows the production of activated sugars for affordable prices. We can synthesize activated sugars from inexpensive substrates using highly efficient multi-enzyme cascades. Our goal is to make them available in for diverse applications in food and pharma. Our cell-free synthesis process is robust and scalable.

Currently available:

UDP-α-D-galactose
UDP-N-acetyl-D-glucosamine
CMP-N-acetylneuraminic acid

Our pipeline:

GDP-L-fucose
UDP-N-acetyl-D-galactosamine

Publications

Rexer TFT et al. Cell-Free Multi-Enzyme Synthesis and Purification of Uridine Diphosphate Galactose. https://doi.org/10.1002/cbic.202100361
Rexer TFT et al. Multi-enzyme Cascades for the In Vitro Synthesis of Guanosine Diphosphate L-Fucose. https://doi.org/10.1002/cctc.202001854
Rexer TFT et al. Enzymatic Synthesis of Glycans and Glycoconjugates. https://doi.org/10.1007/10_2020_148

Order now

For amounts of below 1 gram

For larger amounts

What is a Human Milk Oligosaccharide (HMO)?

Human Milk Oligosaccharides (HMOs) are a diverse family of complex glycans unique to human breast milk. As the third most abundant component after lactose and lipids, HMOs play a crucial role in infant health and development. These remarkable molecules offer a wide range of benefits, including regulating immune system responses, shaping a healthy gut microbiome, and supporting early infant development. Recent research has unveiled the potential of HMOs as valuable food additives and therapeutic agents, sparking significant interest from the food and pharmaceutical industries.

The complexity of HMOs is staggering, with over 200 distinct structures identified to date. Each structure confers unique benefits, making HMOs highly structure-specific in their biological activities. However, the current commercial landscape presents a significant challenge: Only six of the simplest HMO structures are currently available outside of breast milk, leaving the potential benefits of the more complex structures largely untapped.

As research continues to uncover the vast potential of HMOs, there is a growing need for innovative production methods that can unlock the full spectrum of these beneficial compounds. Advancing our ability to synthesize and commercialize a broader range of HMO structures could continue to revolutionize infant nutrition and open new avenues for therapeutic applications across various health domains.

What do we offer?

The synthesis of HMOs is one of the most direct applications of activated sugars. By building upon our activated sugar production platform, we can synthetize a variety of HMOs that would be otherwise complex to obtain by methods like fermentation or chemical synthesis. Most importantly, we are able to produce them at an affordable price. Our goal is to fill in the gap of diverse complex HMOs and bring their nutritional value to the market in diverse applications: Prenatal & Early Life Nutrition, All-age Supplements, Medical Nutrition, and Therapeutics.

Publications

Bode, L. (2012). Human milk oligosaccharides: every baby needs a sugar mama. Glycobiology, 22(9), 1147-1162. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/22513036. doi:10.1093/glycob/cws074
Bode, L. (2015). The functional biology of human milk oligosaccharides. Early Hum Dev, 91(11), 619-622. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/26375354. doi:10.1016/j.earlhumdev.2015.09.001
Plaza-Diaz, J., Fontana, L., & Gil, A. (2018). Human Milk Oligosaccharides and Immune System Development. Nutrients, 10(8). Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/30096792. doi:10.3390/nu10081038

● Prenatal & Early Life Nutrition

● All-age supplements

● Medical Nutrition

● Therapeutics

What is In Vitro Glycoengineering (IVGE)?

The majority of top-selling biopharmaceuticals are glycoproteins, complex molecules whose properties and functions are significantly influenced by their attached glycans (sugar structures). These glycans play a crucial role in determining the pharmacokinetic and pharmacodynamic properties of the biopharmaceutical, including its stability, half-life, and biological activity.

For monoclonal antibodies (mAbs), which represent a large portion of the biopharmaceutical market, the glycoform profile is considered a critical quality attribute (CQA). This means that the specific pattern and composition of glycans attached to the antibody can directly impact its safety and efficacy. As a result, regulatory agencies require biosimilar developers to closely match the glycoform profile of the originator drug when creating a biosimilar version.

One promising approach is in vitro glycoengineering (IVGE), which involves modifying the glycan structures of purified proteins using specific enzymes and activated sugar substrates. This method offers several advantages:

Independence from production process: IVGE can be performed after protein purification, allowing glycan modification without altering the upstream manufacturing process.
Precision: It enables fine-tuning of specific glycan structures to optimize desired properties.
Flexibility: IVGE can be applied to different protein products and adapted to create various glycoforms.
Potential for standardization: This approach could help reduce batch-to-batch variability in glycosylation profiles.

By leveraging IVGE and other glycoengineering techniques, biopharmaceutical companies can potentially enhance the efficacy, stability, and manufacturing consistency of their products, while also facilitating the development of biosimilars that more closely match their reference biologics.

What do we offer?

At eversyn, we offer a comprehensive solution for precise control over protein glycosylation. Our product portfolio includes high-quality, cost-effective activated sugars alongside innovative, highly active enzymes such as glycosyltransferases and glycosidases. These cutting-edge tools empower researchers and biopharmaceutical developers to fine-tune glycoprotein structures with unprecedented precision.

Our vision extends beyond providing individual components; we aim to deliver a readily applicable technology that revolutionizes glycoengineering across scales. By offering robust, scalable solutions, we enable seamless glycosylation optimization from small-scale laboratory experiments to technical-scale production. Moreover, we're paving the way for the integration of advanced glycoengineering techniques into large-scale biopharmaceutical manufacturing processes.

Currently available:

α1,3GalT
α1,6Fuc
Sia2,6T

Publications

Ruhnau, J. et al., 2021. Cell Free Glycoengineering of the Recombinant SARS-CoV-2 Spike Glycoprotein.
https://doi.org/10.3389/fbioe.2021.699025
Rexer, TFT. et al., 2020. Enzymatic Synthesis of Glycans and Glycoconjugates.
https://doi.org/10.1007/10_2020_148

Order now

What is In Vitro Glycoengineering (IVGE)?

What do we offer?

Publications

For amounts of below 500 units

For larger amounts